Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
The FDA approves a combination of aspirin and heartburn medication; Teva partners with Intel to develop wearable; New Mexico AG sues BMS and Sanofi
Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness
New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit
The FDA will hold a public hearing in November to gather input on how it should regulate certain off-label communications.
Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana
The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
FDA Commissioner Robert Califf has two plans for what he wants to achieve during his tenure. One is long-term. The other ends in early 2017.
The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
The FDA said Amgen's biosimilar of Humira is safe and effective; Juno trial halted due to patient deaths; the CMS bans Theranos founder
Donald Trump and Hillary Clinton offer clear contrasts on the issues of the Affordable Care Act, entitlement reform, and drug pricing.
GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center
Opdivo nets sixth Breakthrough Therapy designation; AstraZeneca seeks rare indication to block Crestor generics; Endo mulls sale to reduce debt
A government watchdog criticizes the FDA; the FDA strengthens kidney warnings for Invokana and Farxiga; people with diabetes are living longer
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Industry lobbying group plans counteroffensive; the FDA rejected a record high amount generic drug applications; adcomm recommends Pfizer painkiller
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
U.S. investors want lobbyists to make a better case on drug pricing; pancreatic vaccine failed in Phase-III trial; Epirus cuts 40% of its workforce
The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign
IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service
The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.
Valeant names new CEO; Novartis weighs sales of stake in Roche; FDA ad panel to recommend DMD drug
Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs
The FDA advisory committee voted 12-1 against approving the therapy, citing safety issues and requesting more data.
Analysts have estimated the drug could reach $2 billion in sales in the next four years.
That change is coming about in the wake of a string of First Amendment-based losses for the FDA in federal courts around the country.
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
The FTC asks for more info about Pfizer-Allergan deal; the FDA loosens guidelines for abortion-inducing drug; startup to deliver Truvada through an app
There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Five things for pharma marketers to know: Monday, September 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- The FDA approves Amgen's biosimilar version of Humira
- Five things for pharma marketers to know: Friday, September 23, 2016
- Five things for pharma marketers to know: Thursday, September 22, 2016
- Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
- The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study